CEVEC Pharmaceuticals and Paragon Bioservices, Inc. have announced a joint collaboration earlier whereby Paragon Bioservices would license and use CEVEC's know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

"We are very pleased to be working with Paragon Bioservices," said Wolfgang Kintzel, CEVEC's CEO. "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large."

Paragon's CEO, Marco Chacón, PhD, agrees, "Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business. Everyone needs an edge to meet the outsourcing challenges of our clients. This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC."